BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 4, 2026
Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
Neurology/psychiatric RSS Feed RSS

Illustration of motor neuron connecting to muscle fiber
Neurology/psychiatric

Revir’s RTX-117 designated orphan drug for Charcot-Marie-Tooth disease

Oct. 14, 2025
No Comments
Revir Therapeutics Inc.’s RTX-117 has been awarded orphan drug designation by the FDA for Charcot-Marie-Tooth disease. RTX-117 is a small-molecule therapy designed to activate eIF2B to restore translation of cap-dependent mRNAs to normalize protein expression.
Read More
Neurology/psychiatric

Highly selective HDAC6 inhibitor against neurodegenerative disease

Oct. 14, 2025
No Comments
Inhibiting histone deacetylase 6 (HDAC6) has therapeutic potential against several neurodegenerative disorders. A collaboration including researchers from Eikonizo Therapeutics Inc., spanning the U.K., U.S. and France, developed EKZ-438, which has shown strong potential against amyotrophic lateral sclerosis and frontotemporal dementia in preclinical studies.
Read More
3D rendering of 2-Arachidonoylglycerol (2-AG) endocannabinoid neurotransmitter molecule
Neurology/psychiatric

ECNP 2025: Endocannabinoids have metabolic role in mental health

Oct. 14, 2025
By Anette Breindl
No Comments
At the 2025 European College of Neuropsychopharmacology (ECNP) Congress in Amsterdam this week, researchers presented new findings on the role of endocannabinoids in stress, addiction … and the integrity of the blood-brain-barrier.
Read More
Dollar sign and Euro symbol in cogwheels

Kneu secures $5.6M for neurological disorders platform

Oct. 13, 2025
By Shani Alexander
Who knew? In addition to adopting a new name, Kneu Health Ltd. recently raised $5.6 million in a seed funding round for its smart-phone-based platform which helps to monitor neurological disorders to enable timely intervention. The funds secured will be used to expand commercial operations in the U.S., scale deployments for Parkinson's disease and advance the monitoring capabilities of the platform for dementia.
Read More
Digital 3-D illustration of Japan's flag, light effects

Japan reimagines mental health care through AI

Oct. 13, 2025
By Tamra Sami
Japan is reimagining how mental health care can be delivered digitally and proactively, with local governments investing in digital technology to create data-driven safety nets that aim to detect distress and deliver help, presenters said during the Bio Japan 2025 conference in Yokohama, Oct. 8 to 10.
Read More
3D illustration of a nerve cell
Neurology/psychiatric

Targeting EP2 in Schwann cells blocks pain without inhibiting inflammation

Oct. 13, 2025
No Comments
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat inflammatory pain, but they can have severe side effects, including potentially life-threatening gastrointestinal, renal and cardiac toxicity. Their analgesic effect is driven by inhibition of prostaglandin (PG) biosynthesis and subsequent inflammation, but this inhibitory effect on inflammation could delay pain resolution. An optimal approach to managing PG-mediated pain would selectively relieve pain while preserving the PGs’ essential inflammatory and protective functions.
Read More
Neurology/psychiatric

CSM-101 shows potential utility for Gaucher and Parkinson’s diseases

Oct. 13, 2025
No Comments
Lysosomal homeostasis is crucial to the metabolism of certain proteins and lipids that would otherwise accumulate, thus leading to cellular stress and pathology. This is common in diseases such as Parkinson’s disease and Gaucher disease. Researchers set out to find a brain-penetrant small-molecule agonist of the lysosomal channel TRPML1, also known as mucolipin-1.
Read More
Transmission electron microscopy images of the nanoparticles.
Neurology/psychiatric

Putting the BBB back on track: supramolecular polymersomes for Alzheimer’s

Oct. 13, 2025
By Coia Dulsat
No Comments
Researchers at the Institute for Bioengineering of Catalonia (IBEC) and collaborators have introduced a novel therapeutic strategy for Alzheimer’s disease (AD) that leverages the multivalency of supramolecular nanomedicines to reprogram blood-brain barrier (BBB) function, facilitating efficient amyloid-β (Aβ) clearance and restoring cognitive function in animal models.
Read More
Neurology/psychiatric

Myrobalan Therapeutics describes new GPR17 antagonists

Oct. 10, 2025
Myrobalan Therapeutics Nanjing Co. Ltd. has divulged uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-like) antagonists reported to be useful for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease.
Read More
Neurology/psychiatric

New compounds for anesthesia disclosed in Kelun Pharmaceutical patent

Oct. 10, 2025
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. and Suzhou Kelun Pharmaceutical Co. Ltd. have identified carboxylic acid ester compounds reported to be useful for anesthesia.
Read More
Previous 1 2 … 47 48 49 50 51 52 53 54 55 … 3021 3022 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 4, 2026.
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

    BioWorld Science
    Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
  • EQ-504 is AhR agonist for ulcerative colitis, related disorders

    BioWorld Science
    Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
  • Glucagon-like peptide-1 receptor (GLP-1R) complex

    Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

    BioWorld
    A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing